Combined low doses of PPARγ and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells

American Journal of Pathology

Volumn 175, Issue 3, 2009, Pages 1270-1280

  Bonofiglio, Daniela ^a   Cione, Erika ^a   Qi, Hongyan ^a   Pingitore, Attilio ^a   Perri, Mariarita ^a   Catalano, Stefania ^a   Vizza, Donatella ^a   Panno, Maria Luisa ^a   Genchi, Giuseppe ^a   Fuqua, Suzanne A W ^b   Andò, Sebastiano ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CASPASE 9; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; P21 ACTIVATED KINASE; PROTEIN P53; ROSIGLITAZONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN MCF 7; CELL VIABILITY; DNA FRAGMENTATION; ENZYME ACTIVATION; EPITHELIUM CELL; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LOW DRUG DOSE; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 70349257304     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.081078     Document Type: Article

References (53)

1. Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O: In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs 2008, 17:1623-1633
2. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H: Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009, 27:504-510
3. Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, León A, Esteve J, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA: Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009, 113:775-783
4. Sun SY, Yue P, Mao L, Dawson MI, Shroot B, Lamph WW, Heyman RA, Chandraratna RA, Shudo K, Hong WK, Lotan R: Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 2000, 6:1563-1573 (Pubitemid 30226247)
5. Abu J, Batuwangala M, Herbert K, Symonds P: Retinoic acid and retinoid receptors: potential chemopreventive and therapeutic role in cervical cancer. Lancet Oncol 2005, 6:712-720 (Pubitemid 41222762)
6. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM: The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839 (Pubitemid 126663112)
7. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, Thaller C: 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992, 68:397-406
8. Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998, 95:8806-8811
9. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156
10. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM: Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998, 1:465-470 (Pubitemid 128378895)
11. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, Sporn MB: A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma). GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999, 59:5671-5673
12. Bonofiglio D, Aquila S, Catalano S, Gabriele S, Belmonte M, Middea E, Qi H, Morelli C, Gentile M, Maggiolini M, Andò S: Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Mol Endocrinol 2006, 20:3083-3092 (Pubitemid 44833557)
13. Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, Giordano F, Andò S: Estrogen receptor alpha binds to peroxisome proliferator-activated receptor (PPAR) response element and negatively interferes with PPAR gamma signalling in breast cancer cells. Clin Cancer Res 2005, 11:6139-6147 (Pubitemid 41262940)
14. Bonofiglio D, Gabriele S, Aquila S, Qi H, Belmonte M, Catalano S, Andò S: Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells. Breast Cancer Res Treat 2009, 113:423-434
15. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, Possinger K, Koeffler HP: Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002, 74:155-165 (Pubitemid 34816221)
16. Arakawa K, Ishihara T, Aoto M, Inamasu M, Kitamura K, and Saito A: An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clin Exp Pharmacol Physiol 2004, 31:8-13 (Pubitemid 38230742)
17. Rangwala SM and Lazar MA: Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004, 25:331-336 (Pubitemid 38692426)
18. Staels B: Fluid retention mediated by renal PPARgamma. Cell Metab 2005, 2:77-78
19. Pinaire JA, Reifel-Miller A: Therapeutic potential of retinoid x receptor modulators for the treatment of the metabolic syndrome. PPAR Res 2007, 2007:94156
20. Qin C, Nguyen T, Stewart J, Samudio I, Burghardt R, Safe S: Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor κB/CCAAT-binding transcription factor-1 complex. Mol Endocrinol 2002, 16:1793-1809 (Pubitemid 34830403)
21. Herman ME, Katzenellenbogen BS: Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. J Steroid Biochem Mol Biol 1996, 59:121-134
22. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63
23. Andrews NC, Faller DV: A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991, 19:2499
24. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C: A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′- tetrachloro-1,1′,3,3′ tetraethylbenzimidazolylcarbo-cyanine iodide (JC-1). Biochem Biophys Res Commun 1993, 197:40-45 (Pubitemid 23358874)
25. Mehta RG, Williamson E, Patel MK, Koeffler HP: A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000, 92:418-423 (Pubitemid 30154824)
26. Crowe DL, Chandraratna RA: A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 2004, 6:R546-R555
27. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, Steele GD, Chen LB: Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate forming lipophilic cation JC-1. Proc Natl Acad Sci USA 1991, 88:3671-3675 (Pubitemid 21916685)
28. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM: Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone, and vitamin D3 signaling. Nature 1992, 355:446-449
29. Zhang XK, Hoffmann B, Tran PBV, Graupner G, Pfahl M: Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 1992, 355:441-445
30. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M: Inhibition of human lung cancer cell growth by the peroxisome proliferator activated receptor γ agonists through induction of apoptosis. Biochem Biophys Res Commun 2000, 270:400-405 (Pubitemid 30446848)
31. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y: Peroxisome proliferator activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999, 90:75-80 (Pubitemid 29084314)
32. Roberts-Thomson SJ: Peroxisome proliferator activated receptors in tumorigenesis: targets of tumor promotion and treatment. Immunol Cell Biol 2000, 78:436-441
33. Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S: Induction of solid tumor differentiation by the peroxisome proliferator activated receptor γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999, 96:3951-3956 (Pubitemid 29169017)
34. Yee LD, Williams N, Wen P, Young DC, Lester J, Johnson MV, Farrar WB, Walker MJ, Povoski SP, Suster S, Eng C: Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 2007, 13:246-252 (Pubitemid 46121876)
35. Leblanc BP, Stunnenberg HG: 9-cis retinoic acid signaling: changing partners causes some excitement. Genes Dev 1995, 9:1811-1816
36. Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D: Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-transretinoic acid. Oncogene 2005, 24:8025-8037 (Pubitemid 41746746)
37. Mizuguchi Y, Wada A, Nakagawa K, Ito M, Okano T: Antitumoral activity of 13-demethyl or 13-substituted analogues of all-trans retinoic acid and 9-cis retinoic acid in the human myeloid leukemia cell line HL-60. Biol Pharm Bull 2006, 29:1803-1809 (Pubitemid 44338398)
38. Wan H, Hong WK, Lotan R: Increased retinoic acid responsiveness in lung carcinoma cells that are nonresponsive despite the presence of endogenous retinoic acid receptor (RAR) beta by expression of exogenous retinoid receptors retinoid X receptor alpha, RAR alpha, and RAR gamma. Cancer Res 2001, 61:556-564
39. Wu K, DuPré E, Kim H, Tin-U CK, Bissonnette RP, Lamph WW, Brown PH: Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res Treat 2006, 96:147-157
40. Simeone AM, Tari AM: How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 2004, 61:1475-1484 (Pubitemid 38858353)
41. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: the retinoid X receptor selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998, 58:479-484
42. Grommes C, Landreth GE, Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004, 5:419-429 (Pubitemid 38878045)
43. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, Banayo E, Cardiff RD, Izpisua-Belmonte JC, Evans RM: PPARgamma signaling exacerbates mammary gland tumor development. Genes Dev 2004, 18:528-540 (Pubitemid 38372810)
44. Sporn MB, Suh N, Mangelsdorf DJ: Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 2001, 7:395-400 (Pubitemid 32823988)
45. Wang X, Southard RC, Kilgore MW: The increased expression of peroxisome proliferator-activated receptor-gamma1 in human breast cancer is mediated by selective promoter usage. Cancer Res 2004, 64:5592-5596 (Pubitemid 39095554)
46. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, Kim TS: Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor κB. J Biol Chem 2000, 275:32681-32687 (Pubitemid 30797038)
47. Couturier C, Brouillet A, Couriaud C, Koumanov K, Bereziat G, Andreani M: Interleukin 1beta induces type II-secreted phospholipase A2 gene in vascular smooth muscle cells by a nuclear factor κB and peroxisome proliferator-activated receptor-mediated process. J Biol Chem 1999, 274:23085-23093 (Pubitemid 129529137)
48. Sun YX, Wright HT, Janciasukiene S: Alpha1-antichymotrypsin/Alzheimer's peptide Abeta (1-42) complex perturbs lipid metabolism and activates transcription factors PPARγ and NFκB in human neuroblastoma (Kelly) cells. J Neurosci Res 2002, 67:511-522
49. Ikawa H, Kameda H, Kamitani H, Baek SJ, Nixon JB, His LC, Eling TE: Effect of PPAR activators on cytokine stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Exp Cell Res 2001, 267:73-80 (Pubitemid 32579142)
50. Schlezinger JJ, Jensen BA, Mann KK, Ryu HY, Sherr DH: Peroxisome proliferator-activated receptor γ-mediated NFkB activation and apoptosis in pre-B cells. J Immunol 2002, 169:6831-6841 (Pubitemid 36899268)
51. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JMW, Harper ME, Barrow D, Wakeling AE, Nicholson RI: Elevated levels of EGFR/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044 (Pubitemid 36262870)
52. Jones HE, Goddard L, Gee JMW, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S. Wakeling AE, Nicholson RI: Insulin-like growth factor-I receptor signaling and acquired resistance to gefitinib (ZD1839, Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004, 11:793-814 (Pubitemid 40065552)
53. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI: Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2005, 7:1-12 (Pubitemid 43945756)